Agomab lists director Patel with no AGMB holdings

Agomab Therapeutics NV reported director Naimish Patel as an insider on a Form 3 with no holdings or trades disclosed.

Rhea-AI Filing Summary

Agomab Therapeutics NV (AGMB) filed an initial ownership report for Naimish Patel, who is identified as a director of the company. The Form 3 does not report any equity holdings or transactions by the director, and the only additional item referenced is an Exhibit 24 Power of Attorney.

Key Terms

Form 3, Power of Attorney, initial ownership report

3 terms

Form 3 regulatory

"filed an initial ownership report for Naimish Patel"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Power of Attorney regulatory

"The only additional item referenced is an Exhibit 24 Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

initial ownership report regulatory

"filed an initial ownership report for Naimish Patel"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for AGMB disclose about Naimish Patel?

The Form 3 identifies Naimish Patel as a director of Agomab Therapeutics NV (AGMB). It reports no stock or derivative holdings and no transactions for him at the time of this initial ownership statement.

Does the AGMB Form 3 show any stock purchases or sales by the director?

No. The Form 3 for Agomab Therapeutics NV shows no reported transactions by director Naimish Patel. Buy, sell, acquire, dispose, exercise, and gift counts and share amounts are all shown as zero.

Are any AGMB shares or options reported as held by Naimish Patel on this Form 3?

No. The structured data for the filing shows zero holding entries and an empty derivative summary, indicating that no common stock or derivative positions are reported for Naimish Patel on this Form 3.

Does the AGMB Form 3 reference a Rule 10b5-1 trading plan for the director?

No. The Form 3 contains no indication that any transactions were made under a Rule 10b5-1 trading plan, and it reports no trades for Naimish Patel.

What additional document is mentioned in the AGMB Form 3 remarks?

The remarks section notes “Exhibit 24 - Power of Attorney”, indicating that a power of attorney authorizing the signing of SEC filings on behalf of the reporting person is included as an exhibit to the Form 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:06 PM Accepted by SEC EDGAR 09/15/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Patel Naimish

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/11/2026

3. Issuer Name and Ticker or Trading Symbol
AgomAb Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Ellen Lefever, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)